5-bromo-2-methylpyrazolo[4,3-b]pyridine | 1563177-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 5-bromo-2-methylpyrazolo[4,3-b]pyridine
• 英文别名: 5-Bromo-2-methyl-2H-pyrazolo[4,3-b]pyridine
• CAS: 1563177-30-9
• 化学式: C₇H₆BrN₃
• 分子量: 212.049
• InChiKey: NPMHAXUGFDCTLE-UHFFFAOYSA-N

物化性质

• 沸点：
  335.9±22.0 °C(Predicted)
• 密度：
  1.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-2-methylpyrazolo[4,3-b]pyridine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 四(三苯基膦)钯 、 potassium acetate 、 lithium chloride 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 反应 69.0h， 生成 5-(3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine
  参考文献：
  名称：

  [EN] HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME
  [FR] COMPOSÉS DE 1,3,4-THIADIAZOLE ET DE PYRIDAZINE SUBSTITUÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure may act as small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded genes, and methods of use of the compounds for modulating splicing and treating related diseases and conditions. The compounds disclosed herein may possess activity toward various genetic pathways and are accordingly useful in methods of treatment of the human or animal body.

  公开号：

  WO2023092149A1
• 作为产物：
  描述：

  2-溴-5-氨基-6-甲基吡啶 在 potassium acetate 、 乙酸酐 、 potassium carbonate 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 生成 5-bromo-2-methylpyrazolo[4,3-b]pyridine
  参考文献：
  名称：

  [EN] HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME
  [FR] COMPOSÉS DE 1,3,4-THIADIAZOLE ET DE PYRIDAZINE SUBSTITUÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure may act as small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded genes, and methods of use of the compounds for modulating splicing and treating related diseases and conditions. The compounds disclosed herein may possess activity toward various genetic pathways and are accordingly useful in methods of treatment of the human or animal body.

  公开号：

  WO2023092149A1

文献信息

• [EN] 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE ET COMPOSÉS Y RELATIFS EN TANT QUE MODULATEURS POUR L'ÉPISSAGE D'ACIDES NUCLÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRANTES
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2022006550A1

  公开（公告）日：2022-01-06

  The present disclosure features compounds of formula (l-a) and of formula (II) and pharmaceutical compositions thereof. The present disclosure further discloses the compounds of formula (I- a) and (II) and their compositions for use in methods of modulating nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as said compounds for use in methods of treating e.g.: • proliferative diseases, such as e.g. cancer, benign neoplasms or angiogenesis, • neurological diseases or disorders, such as e.g. Huntington's disease, • autoimmune diseases or disorders, immunodeficiency diseases or disorders, lysosomal storage disease or disorder, cardiovascular diseases or disorders, metabolic diseases or disorders, respiratory diseases or disorders, renal diseases or disorders, or infectious diseases. Exemplary compounds are e.g. 2-(indazol-5-yl)-6-(piperidin-4-yl)-l,7- naphthyridine derivatives and similar compounds.

  本公开涉及公式(l-a)和公式(II)的化合物及其药物组合物。本公开还揭示了公式(I-a)和(II)的化合物及其组合物，用于调节核酸剪接的方法，例如，剪接预mRNA，以及用于治疗方法的化合物，例如： •增殖性疾病，如癌症、良性肿瘤或血管生成等， •神经系统疾病或障碍，如亨廷顿病等， •自身免疫性疾病或障碍、免疫缺陷性疾病或障碍、溶酶体贮积病或障碍、心血管疾病或障碍、代谢性疾病或障碍、呼吸系统疾病或障碍、肾脏疾病或障碍或传染性疾病。示例化合物包括2-(吲哚-5-基)-6-(哌啶-4-基)-1,7-萘啶衍生物和类似化合物。